Zhejiang Hengkang expands API and oligonucleotide manufacturing

By AI, Created 10:23 AM UTC, May 20, 2026, /AGP/ – Zhejiang Hengkang Pharmaceutical says it is widening its global supply and development capabilities as demand rises for APIs, specialty intermediates and oligonucleotide-based therapies. The company is leaning on manufacturing upgrades, quality systems and international expansion to serve pharmaceutical and biotech customers.

Why it matters: - Zhejiang Hengkang Pharmaceutical is positioning itself to benefit from rising demand for high-quality active pharmaceutical ingredients, specialty intermediates and advanced therapeutic technologies. - The company’s expansion matters because pharmaceutical buyers are prioritizing supply chain security, regulatory reliability and scalable production. - Oligonucleotide manufacturing is becoming more important as biotech firms push gene-targeted treatments, molecular diagnostics and precision medicine.

What happened: - Zhejiang Hengkang Pharmaceutical Co., Ltd. said on May 9, 2026, that it is strengthening its role in the global API market. - The company said it is expanding research-driven development and global supply capabilities for pharmaceutical customers. - Zhejiang Hengkang Pharmaceutical said its business now includes API products, oligonucleotide technologies and customized pharmaceutical development solutions. - The company listed its address as No.11 Chengen Road, Pubagang Town, Sanmen County, Zhejiang Province, China. - The company’s website is More information.

The details: - Zhejiang Hengkang Pharmaceutical says it focuses on the development and manufacturing of high-value pharmaceutical ingredients for pharmaceutical companies, biotech firms and healthcare manufacturers. - The company said it has invested in specialized oligonucleotide production capabilities. - Zhejiang Hengkang Pharmaceutical said it has improved process optimization and technical development to support both research and commercial-scale manufacturing. - The company said it uses comprehensive quality management systems to support stable production performance and international regulatory alignment. - Zhejiang Hengkang Pharmaceutical said it has strengthened manufacturing systems through facility upgrades, technical equipment investments and operational standardization. - The company said its operations include process validation, raw material management, analytical testing and production monitoring. - Zhejiang Hengkang Pharmaceutical said it has expanded international business operations to support overseas markets and export capability. - The company said it continues to optimize production processes to improve efficiency and support sustainability goals.

Between the lines: - The release reflects a broader industry shift toward manufacturers that can combine biotechnology expertise with reliable large-scale production. - The focus on oligonucleotides suggests Zhejiang Hengkang is aiming at faster-growing segments of pharmaceutical research, not just traditional API supply. - The emphasis on compliance and logistics signals that global customers are looking for partners that can reduce supply risk as well as deliver product.

What’s next: - Zhejiang Hengkang Pharmaceutical is expected to keep investing in research collaboration, process innovation and manufacturing scale. - The company is likely to keep targeting international pharmaceutical and biotech buyers as demand for advanced therapeutics grows. - Continued competition in the API market will likely reward suppliers that can prove quality, consistency and export readiness.

The bottom line: - Zhejiang Hengkang Pharmaceutical is trying to turn manufacturing upgrades and oligonucleotide investment into a bigger role in global pharmaceutical supply.